314 related articles for article (PubMed ID: 26297257)
1. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
Choi YW; Kim YH; Lee J; Soh EY; Park TJ; Kim JH
Hum Pathol; 2015 Oct; 46(10):1557-65. PubMed ID: 26297257
[TBL] [Abstract][Full Text] [Related]
2. LGR5 is associated with tumor aggressiveness in papillary thyroid cancer.
Michelotti G; Jiang X; Sosa JA; Diehl AM; Henderson BB
Oncotarget; 2015 Oct; 6(33):34549-60. PubMed ID: 26416247
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
4. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
[TBL] [Abstract][Full Text] [Related]
6. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
[TBL] [Abstract][Full Text] [Related]
7. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR.
Zhang J; Yang Y; Zhao J; Shi L; Xu Y; Yu K; Guo C
Pathol Res Pract; 2019 Apr; 215(4):761-765. PubMed ID: 30819583
[TBL] [Abstract][Full Text] [Related]
8. [Association between BRAF V600E mutation and central lymph node metastasis in patients with papillary thyroid carcinoma].
Shi C; Qin H; Ding C; Sun Y; Lyu Y; Shi T
Zhonghua Zhong Liu Za Zhi; 2015 Feb; 37(2):123-7. PubMed ID: 25975689
[TBL] [Abstract][Full Text] [Related]
9. Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation.
Stojanović S; Šelemetjev S; Đorić I; Rončević J; Janković Miljuš J; Živaljević V; Išić Denčić T
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1835-1842. PubMed ID: 32651027
[TBL] [Abstract][Full Text] [Related]
10. The thyroid imaging reporting and data system on US, but not the BRAFV600E mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC.
Park VY; Kim EK; Moon HJ; Yoon JH; Kwak JY
Medicine (Baltimore); 2016 Jul; 95(29):e4292. PubMed ID: 27442672
[TBL] [Abstract][Full Text] [Related]
11. The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.
Czarniecka A; Kowal M; Rusinek D; Krajewska J; Jarzab M; Stobiecka E; Chmielik E; Zembala-Nozynska E; Poltorak S; Sacher A; Maciejewski A; Zebracka-Gala J; Lange D; Oczko-Wojciechowska M; Handkiewicz-Junak D; Jarzab B
PLoS One; 2015; 10(7):e0132821. PubMed ID: 26177218
[TBL] [Abstract][Full Text] [Related]
12. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.
Pasquali D; Santoro A; Bufo P; Conzo G; Deery WJ; Renzullo A; Accardo G; Sacco V; Bellastella A; Pannone G
Thyroid; 2011 Apr; 21(4):391-9. PubMed ID: 21385081
[TBL] [Abstract][Full Text] [Related]
14. The relationship between BRAFV600E, NF-κB and TgAb expression in papillary thyroid carcinoma.
Li W; Ming H; Sun D; Li W; Wang D; Zhang G; Tan J
Pathol Res Pract; 2017 Mar; 213(3):183-188. PubMed ID: 28214213
[TBL] [Abstract][Full Text] [Related]
15. BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience.
Pelizzo MR; Boschin IM; Barollo S; Pennelli G; Toniato A; Zambonin L; Vianello F; Piotto A; Ide EC; Pagetta C; Sorgato N; Torresan F; Girelli ME; Nacamulli D; Mantero F; Mian C
Clin Chem Lab Med; 2011 Feb; 49(2):325-9. PubMed ID: 21175381
[TBL] [Abstract][Full Text] [Related]
16. BRAFV600E Immunohistochemistry in Papillary Thyroid Carcinomas: Relationship Between Clinical and Morphological Parameters.
Kombak FE; Özkan N; Uğurlu MÜ; Kaya H
Turk Patoloji Derg; 2019; 35(2):83-91. PubMed ID: 30632125
[TBL] [Abstract][Full Text] [Related]
17. Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data.
Chai YJ; Yi JW; Jee HG; Kim YA; Kim JH; Xing M; Lee KE
PLoS One; 2016; 11(7):e0159235. PubMed ID: 27410688
[TBL] [Abstract][Full Text] [Related]
18. Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer.
Shao H; Yu X; Wang C; Wang Q; Guan H
Endocrine; 2014 Jun; 46(2):285-91. PubMed ID: 24272599
[TBL] [Abstract][Full Text] [Related]
19. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
[TBL] [Abstract][Full Text] [Related]
20. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status.
Paskaš S; Janković J; Marečko I; Išić Denčić T; Tatić S; Cvejić D; Savin S
Otolaryngol Head Neck Surg; 2014 Feb; 150(2):201-9. PubMed ID: 24255086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
